Forbion Raises €2.3 Billion Across Two New Life Sciences Funds

Forbion has raised €2.3 billion across two new life sciences funds, according to a report by Pulse 2.0.

The raise is one of the largest commitments to European life sciences venture capital in recent memory. Pulse 2.0 reported the figure as the combined total across the two vehicles, which will back companies in the biomedical and broader life sciences sector.

What does the €2.3 billion buy?

The capital will flow into two distinct funds under the Forbion banner. Pulse 2.0 did not break down the split between the vehicles in its report, but the combined €2.3 billion gives the firm substantial dry powder at a time when life sciences fundraising has tightened across Europe and the United States.

Forbion has built its franchise on investing in biopharmaceutical and medical technology companies from early stage through growth equity. The new funds extend that strategy with significantly enlarged resources.

Why does the size matter?

A €2.3 billion close signals sustained limited-partner appetite for life sciences exposure despite a difficult fundraising environment for venture capital generally. Pension funds, endowments and other institutional investors have grown more selective since 2022, and large closes of this scale tend to concentrate capital with established managers.

For portfolio companies, the implication is straightforward: Forbion now holds the resources to lead large financing rounds and support its companies through later-stage development without relying on external syndicates.

Pulse 2.0's report did not specify the target sectors, geographic focus or final close timing for the two funds.

The raise positions Forbion to deploy capital into new and existing life sciences companies over the coming years, and the firm's investment pace will be a signal of where biomedical venture demand is heading next.